Verkazia
ciclosporin · Santen Oy
ORPHAN AUTHORISED IN THE EUWhat Verkazia is used for
Treatment of severe vernal keratoconjunctivitis (VKC) in children from 4 years of age and adolescents.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Verkazia
- Active substance
- ciclosporin
- Disease area
- Conjunctivitis; Keratitis
- Medicine group
- Ophthalmologicals
- ATC code
- S01XA18
- Marketing authorisation holder
- Santen Oy
- Authorised in the EU since
- 2018
Official information
In India
- Ciclosporin: 89 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Verkazia used for?
Treatment of severe vernal keratoconjunctivitis (VKC) in children from 4 years of age and adolescents.
What is the active substance in Verkazia?
Verkazia contains ciclosporin.
Who makes Verkazia?
The EU marketing authorisation holder is Santen Oy.
Is Verkazia an orphan medicine?
Yes. Verkazia is designated an orphan medicine in the EU, for a rare disease (Conjunctivitis; Keratitis).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU